Boston Scientific valuation
Valuation
The P/E ratio is 18.4. The average price target of 28 analysts is $49.60.
Data as of November 17, 2026
Boston Scientific compared with similar companies
Boston Scientific's P/E (trailing 12 months): 18.4, −40% against the median of a group of 11 similar companies (30.5).
| Metric | Boston Scientific | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 18.4 | 30.5 | 24.4 – 36.6 | Low |
| Forward P/E | 14.0 | 18.4 | 15.4 – 23.4 | Low |
| EV/EBITDA | 13.5 | 16.1 | 14.0 – 19.3 | Low |
| Price/book | 2.47 | 3.65 | 2.90 – 6.03 | Low |
| Price/sales | 3.01 | 3.86 | 3.08 – 5.23 | Low |
| Gross margin | 68.0% | 65.7% | 60.3% – 68.7% | Middle |
| Operating margin | 19.6% | 19.2% | 16.2% – 22.0% | Middle |
| Net margin | 16.6% | 13.4% | 10.0% – 14.6% | High |
| ROE | 14.1% | 11.6% | 10.0% – 18.0% | Middle |
| Debt/equity | 0.46 | 0.55 | 0.37 – 0.63 | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Boston Scientific: valuation over time
On the latest fiscal year's earnings (2025), Boston Scientific's P/E today is 22.3, below the median of its last 8 fiscal years (57.8; between 13.6 and 102.8 from 2016 to 2025). Relative to earnings, the stock costs less than it used to.
| Fiscal year | Price at year end | Earnings per share | P/E |
|---|---|---|---|
| 2025 | $95.35 | $1.94 | 49.1 |
| 2024 | $89.32 | $1.25 | 71.5 |
| 2023 | $57.81 | $1.07 | 54.0 |
| 2022 | $46.27 | $0.45 | 102.8 |
| 2021 | $42.48 | $0.69 | 61.6 |
| 2020 | $35.95 | -$0.08 | — |
| 2019 | $45.22 | $3.33 | 13.6 |
| 2018 | $35.34 | $1.19 | 29.7 |
| 2017 | $24.79 | $0.08 | — |
| 2016 | $21.63 | $0.25 | 86.5 |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only). Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- $63.33B
- Enterprise value
- $74.91B
- PEG
- 0.75
- EV/revenue
- 3.56
Profitability and growth
- ROA
- 5.9%
- ROIC
- 7.0%
- Revenue growth (year over year)
- 1.4%
- Earnings growth (year over year)
- -21.5%
Financial health
- Total cash
- $609M
- Total debt
- $11.95B
- Current ratio
- 1.37
- Quick ratio
- 0.62
- Altman Z-Score
- 4.24
- Piotroski F-Score
- 5.00
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $49.60
- Median price target
- $49.00
- High price target
- $60.00
- Low price target
- $41.00
- Analysts with a price target
- 28
- Consensus
- Buy
- Forward EPS
- $3.13
- EPS estimate, current year
- $3.17
Shares and trading
- Beta
- 0.59
- Average volume
- 19.62M
- Shares outstanding
- 1.45B
- Float
- 1.44B
- Institutional ownership
- 96.9%
- Insider ownership
- 0.3%
- Short interest (% of float)
- 2.4%
- Short ratio (days)
- 1.90
